• Something wrong with this record ?

A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers

S. Budhathoki, B. Diergaarde, G. Liu, A. Olshan, A. Ness, T. Waterboer, S. Virani, P. Basta, N. Bender, N. Brenner, T. Dudding, N. Hayes, A. Hope, SH. Huang, K. Hueniken, B. Kanterewicz, JD. McKay, M. Pring, S. Thomas, K. Wisniewski, S. Thomas,...

. 2023 ; 152 (10) : 2069-2080. [pub] 20230201

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural

Persistent link   https://www.medvik.cz/link/bmc23003590

Grant support
R01 DE025712 NIDCR NIH HHS - United States
P30 CA047904 NCI NIH HHS - United States
C18281/A19169 Cancer Research UK - United Kingdom
CIHR - Canada
RP-PG-0707-10034 Department of Health - United Kingdom
P50 CA097190 NCI NIH HHS - United States

Head and neck cancer is often diagnosed late and prognosis for most head and neck cancer patients remains poor. To aid early detection, we developed a risk prediction model based on demographic and lifestyle risk factors, human papillomavirus (HPV) serological markers and genetic markers. A total of 10 126 head and neck cancer cases and 5254 controls from five North American and European studies were included. HPV serostatus was determined by antibodies for HPV16 early oncoproteins (E6, E7) and regulatory early proteins (E1, E2, E4). The data were split into a training set (70%) for model development and a hold-out testing set (30%) for model performance evaluation, including discriminative ability and calibration. The risk models including demographic, lifestyle risk factors and polygenic risk score showed a reasonable predictive accuracy for head and neck cancer overall. A risk model that also included HPV serology showed substantially improved predictive accuracy for oropharyngeal cancer (AUC = 0.94, 95% CI = 0.92-0.95 in men and AUC = 0.92, 95% CI = 0.88-0.95 in women). The 5-year absolute risk estimates showed distinct trajectories by risk factor profiles. Based on the UK Biobank cohort, the risks of developing oropharyngeal cancer among 60 years old and HPV16 seropositive in the next 5 years ranged from 5.8% to 14.9% with an average of 8.1% for men, 1.3% to 4.4% with an average of 2.2% for women. Absolute risk was generally higher among individuals with heavy smoking, heavy drinking, HPV seropositivity and those with higher polygenic risk score. These risk models may be helpful for identifying people at high risk of developing head and neck cancer.

Bristol Dental School University of Bristol Bristol UK

Catalan Institute of Oncology IDIBELL Barcelona Spain

Centre for Oral Health Research Newcastle University Newcastle upon Tyne UK

Dalla Lana School of Public Health University of Toronto Toronto Ontario Canada

Department of Epidemiology Gillings School of Global Public Health University of North Carolina Chapel Hill North Carolina USA

Department of Medical Oncology Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada

Department of Radiation Oncology Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada

Division of Medical Oncology and Center for Cancer Research University of Tennessee Health Science Center Memphis Tennessee USA

Epidemiology Group School of Medicine Medical Sciences and Nutrition University of Aberdeen Aberdeen UK

Genetic Epidemiology Group International Agency for Research on Cancer Lyon France

Graduate School of Public Health University of Pittsburgh and UPMC Hillman Cancer Center Pittsburgh Pennsylvania USA

Infections and Cancer Epidemiology Division German Cancer Research Center Heidelberg Germany

Institute of Hygiene and Epidemiology Prague Czech Republic

International Agency for Research on Cancer Lyon France

National Cancer Institute IRCCS Milan Italy

NIHR Bristol Biomedical Research Centre Weston NHS Foundation Trust University of Bristol Bristol UK

Nutrition and Cancer Group Epidemiology Public Health Cancer Prevention and Palliative Care Program Bellvitge Biomedical Research Institute IDIBELL L'Hospitalet de Llobregat Barcelona Spain

Prosserman Centre for Population Health Research Lunenfeld Tanenbaum Research Institute Sinai Health Toronto Ontario Canada

Radiation Medicine Program Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada

Reference Centre for Epidemiology and Cancer Prevention in Piemonte University of Turin Aberdeen Italy

School of Dental Science Trinity College Dublin Dublin Ireland

School of Medicine Dentistry and Nursing University of Glasgow Glasgow UK

School of Medicine National and Kapodistrian University of Athens Zografou Greece

School of Public Health University of West Attica Aigaleo Greece

Unit of Biostatistics Epidemiology and Public Health Department of Cardio Thoraco Vascular Sciences and Public Health University of Padua Padova Italy

Unit of Nutrition and Cancer Catalan Institute of Oncology ICO L'Hospitalet de Llobregat Barcelona Spain

University of North Carolina Lineberger Cancer Center Chapel Hill North Carolina USA

UPMC Hillman Cancer Center Pittsburgh Pennsylvania USA

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003590
003      
CZ-PrNML
005      
20230425140740.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.34444 $2 doi
035    __
$a (PubMed)36694401
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Budhathoki, Sanjeev $u Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada $1 https://orcid.org/0000000316623109
245    12
$a A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers / $c S. Budhathoki, B. Diergaarde, G. Liu, A. Olshan, A. Ness, T. Waterboer, S. Virani, P. Basta, N. Bender, N. Brenner, T. Dudding, N. Hayes, A. Hope, SH. Huang, K. Hueniken, B. Kanterewicz, JD. McKay, M. Pring, S. Thomas, K. Wisniewski, S. Thomas, Y. Brhane, A. Agudo, L. Alemany, A. Lagiou, L. Barzan, C. Canova, DI. Conway, CM. Healy, I. Holcatova, P. Lagiou, GJ. Macfarlane, TV. Macfarlane, J. Polesel, L. Richiardi, M. Robinson, A. Znaor, P. Brennan, RJ. Hung
520    9_
$a Head and neck cancer is often diagnosed late and prognosis for most head and neck cancer patients remains poor. To aid early detection, we developed a risk prediction model based on demographic and lifestyle risk factors, human papillomavirus (HPV) serological markers and genetic markers. A total of 10 126 head and neck cancer cases and 5254 controls from five North American and European studies were included. HPV serostatus was determined by antibodies for HPV16 early oncoproteins (E6, E7) and regulatory early proteins (E1, E2, E4). The data were split into a training set (70%) for model development and a hold-out testing set (30%) for model performance evaluation, including discriminative ability and calibration. The risk models including demographic, lifestyle risk factors and polygenic risk score showed a reasonable predictive accuracy for head and neck cancer overall. A risk model that also included HPV serology showed substantially improved predictive accuracy for oropharyngeal cancer (AUC = 0.94, 95% CI = 0.92-0.95 in men and AUC = 0.92, 95% CI = 0.88-0.95 in women). The 5-year absolute risk estimates showed distinct trajectories by risk factor profiles. Based on the UK Biobank cohort, the risks of developing oropharyngeal cancer among 60 years old and HPV16 seropositive in the next 5 years ranged from 5.8% to 14.9% with an average of 8.1% for men, 1.3% to 4.4% with an average of 2.2% for women. Absolute risk was generally higher among individuals with heavy smoking, heavy drinking, HPV seropositivity and those with higher polygenic risk score. These risk models may be helpful for identifying people at high risk of developing head and neck cancer.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lidské papilomaviry $7 D000094302
650    12
$a infekce papilomavirem $7 D030361
650    _2
$a genetické markery $7 D005819
650    12
$a nádory hlavy a krku $7 D006258
650    12
$a nádory orofaryngu $7 D009959
650    _2
$a rizikové faktory $7 D012307
650    _2
$a lidský papilomavirus 16 $x genetika $7 D052162
650    _2
$a protilátky virové $7 D000914
650    _2
$a transkripční faktory $x genetika $7 D014157
650    12
$a onkogenní proteiny virové $x genetika $7 D009856
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Diergaarde, Brenda $u Graduate School of Public Health, University of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
700    1_
$a Liu, Geoffrey $u Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada $u Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Olshan, Andrew $u University of North Carolina Lineberger Cancer Center, Chapel Hill, North Carolina, USA
700    1_
$a Ness, Andrew $u NIHR Bristol Biomedical Research Centre, Weston NHS Foundation Trust, University of Bristol, Bristol, UK $u Bristol Dental School, University of Bristol, Bristol, UK
700    1_
$a Waterboer, Tim $u Infections and Cancer Epidemiology Division, German Cancer Research Center (DKFZ), Heidelberg, Germany
700    1_
$a Virani, Shama $u Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
700    1_
$a Basta, Patricia $u Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA
700    1_
$a Bender, Noemi $u Infections and Cancer Epidemiology Division, German Cancer Research Center (DKFZ), Heidelberg, Germany
700    1_
$a Brenner, Nicole $u Infections and Cancer Epidemiology Division, German Cancer Research Center (DKFZ), Heidelberg, Germany
700    1_
$a Dudding, Tom $u Bristol Dental School, University of Bristol, Bristol, UK $1 https://orcid.org/000000033756040X
700    1_
$a Hayes, Neil $u Division of Medical Oncology and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee, USA
700    1_
$a Hope, Andrew $u Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada $u Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Huang, Shao Hui $u Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Hueniken, Katrina $u Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Kanterewicz, Beatriz $u UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
700    1_
$a McKay, James D $u Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
700    1_
$a Pring, Miranda $u Bristol Dental School, University of Bristol, Bristol, UK
700    1_
$a Thomas, Steve $u Bristol Dental School, University of Bristol, Bristol, UK
700    1_
$a Wisniewski, Kathy $u Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA
700    1_
$a Thomas, Sera $u Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada
700    1_
$a Brhane, Yonathan $u Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada
700    1_
$a Agudo, Antonio $u Unit of Nutrition and Cancer, Catalan Institute of Oncology - ICO, L'Hospitalet de Llobregat, Barcelona, Spain $u Nutrition and Cancer Group, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
700    1_
$a Alemany, Laia $u Catalan Institute of Oncology/IDIBELL, Barcelona, Spain
700    1_
$a Lagiou, Areti $u School of Public Health, University of West Attica, Aigaleo, Greece
700    1_
$a Barzan, Luigi $u National Cancer Institute, IRCCS, Milan, Italy
700    1_
$a Canova, Cristina $u Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padova, Italy
700    1_
$a Conway, David I $u School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, UK $1 https://orcid.org/0000000177624063
700    1_
$a Healy, Claire M $u School of Dental Science, Trinity College Dublin, Dublin, Ireland
700    1_
$a Holcatova, Ivana $u Institute of Hygiene and Epidemiology, Prague, Czech Republic
700    1_
$a Lagiou, Pagona $u School of Medicine, National and Kapodistrian University of Athens, Zografou, Greece
700    1_
$a Macfarlane, Gary J $u Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
700    1_
$a Macfarlane, Tatiana V $u Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
700    1_
$a Polesel, Jerry $u National Cancer Institute, IRCCS, Milan, Italy $1 https://orcid.org/0000000193811520
700    1_
$a Richiardi, Lorenzo $u Reference Centre for Epidemiology and Cancer Prevention in Piemonte, University of Turin, Aberdeen, Italy
700    1_
$a Robinson, Max $u Centre for Oral Health Research, Newcastle University, Newcastle upon Tyne, UK
700    1_
$a Znaor, Ariana $u International Agency for Research on Cancer, Lyon, France $1 https://orcid.org/0000000258494782
700    1_
$a Brennan, Paul $u Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France $1 https://orcid.org/0000000205188714
700    1_
$a Hung, Rayjean J $u Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada $u Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada $1 https://orcid.org/0000000244867496
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 152, č. 10 (2023), s. 2069-2080
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36694401 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140737 $b ABA008
999    __
$a ok $b bmc $g 1924337 $s 1189799
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 152 $c 10 $d 2069-2080 $e 20230201 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
GRA    __
$a R01 DE025712 $p NIDCR NIH HHS $2 United States
GRA    __
$a P30 CA047904 $p NCI NIH HHS $2 United States
GRA    __
$a C18281/A19169 $p Cancer Research UK $2 United Kingdom
GRA    __
$p CIHR $2 Canada
GRA    __
$a RP-PG-0707-10034 $p Department of Health $2 United Kingdom
GRA    __
$a P50 CA097190 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20230418
Back

Find record

Citation metrics

Archiving options